Kazia Therapeuti Stock Price, News & Analysis

Kazia Therapeutics Limited (NASDAQ: KZIA) announced promising final results from its Phase II clinical study of paxalisib as a first-line treatment for glioblastoma (NCT03522298). The study involved 30 patients with newly diagnosed disease, revealing a median overall survival of 15.7 months, outperforming the historical 12.7 months with temozolomide. Progression-free survival was also notable at 8.4 months compared to 5.3 months for the standard treatment. The maximum tolerated dose of paxalisib was set at 60mg daily. Kazia aims to publish these findings in a peer-reviewed journal in 2022.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announces the opening of the GBM AGILE study in glioblastoma at Sunnybrook Health Sciences Centre in Toronto, marking Canada's first site for paxalisib recruitment. This expansion into Canada allows Canadian patients to access potential new treatment options for glioblastoma, which affects approximately 1,200 Canadians annually. The study aims to enroll up to 200 patients on paxalisib and will include sites in the US, with plans to expand to Europe and China in the coming months.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced the appointment of John Friend, MD, as Chief Medical Officer. Dr. Friend will lead the development and commercialization of Kazia's oncology drug pipeline, including paxalisib and EVT801. With over 25 years of experience, Dr. Friend previously served as CMO at Cellectar Biosciences and held senior positions at Helsinn Therapeutics. His expertise is expected to enhance Kazia's research initiatives, especially as paxalisib advances toward commercialization.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced the initiation of the PNOC022 study at the University of California, San Francisco, focusing on DIPG and diffuse midline gliomas, with the first patient successfully enrolled. This phase II study will investigate the efficacy of Kazia's investigational drug, paxalisib, in various treatment arms. DIPG is a highly aggressive childhood brain cancer with no FDA-approved treatments. The study aims to recruit several hundred patients and will utilize novel trial designs to explore combination therapies, making it a significant step in pediatric oncology.

Kazia Therapeutics Limited (KZIA) has commenced patient enrollment for a Phase I clinical trial of EVT801, an investigational cancer therapy. Licensed from Evotec SE in April 2021, EVT801 targets VEGFR3 to inhibit lymphangiogenesis, showing promising preclinical results. The trial aims to assess safety, tolerability, and pharmacokinetics while exploring preliminary efficacy signals through biomarker analyses. The study will recruit up to 60 patients at the IUCT-Oncopole in Toulouse, France, focusing on renal cell carcinoma and soft-tissue sarcoma. Kazia anticipates further updates as the trial progresses.

Kazia Therapeutics anticipates releasing critical data from its paxalisib program in Q4 2021, including results from a 30-patient Phase II trial for newly diagnosed glioblastoma multiforme and initial data for treating brain metastases. The company has raised its valuation to US$277 million or US$20.92 per basic ADR, which reflects a forward adjustment in its NPV, despite lower net cash of US$20.4 million as of June 30, 2021. Kazia's financing requirement has increased to US$44 million, driven by heightened R&D expenditure.

Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the LD Micro Main Event from October 12-14, 2021. CEO Dr. James Garner will discuss significant developments in 2021, including three cross-border licensing deals and the start of an international pivotal study for its lead asset, paxalisib. The hybrid event will feature around 120 companies, with the Kazia presentation scheduled for 10 AM ET on October 12. Registration for the conference is complimentary and available through the conference website.

Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the HC Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dr. James Garner will discuss the company's pivotal study on paxalisib, aimed at treating glioblastoma, which affects over 12,500 patients annually. The market potential for this treatment is valued at US$ 1.5 billion. Significant developments include an out-licensing deal for pazalisib in Greater China and in-licensing of another oncology asset, EVT801. Dr. Garner will also outline Kazia's objectives for FY2022.

Kazia Therapeutics Limited (NASDAQ: KZIA) highlights Glioblastoma (GBM) Awareness Day on July 21, 2021, urging increased research focus on this aggressive brain cancer, which affects around 13,000 Americans annually. Current GBM treatments yield limited benefits, with median survival at 16 months. CEO Dr. James Garner expresses confidence in future treatment advancements, particularly with the drug paxalisib, currently in phase II trials. Kazia calls for collaboration among stakeholders to improve GBM treatment prospects.